Many male survivors of childhood cancer do not think they are at increased risk for sexual dysfunction, including some who underwent gonadotoxic chemotherapy or radiation to the pelvis, according to research published in Cancer. Read more: https://www.cancertherapyadvisor.com/news/male-childhood-cancer-survivors-underestimate-sexual-dysfunction/

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified candidate treatment targets and potential prognostic markers for high-grade glioma, an aggressive brain cancer, in children, adolescents, and young adults. Read more: https://www.mountsinai.org/about/newsroom/2026/study-identifies-candidate-treatment-targets-for-high-grade-glioma-in-children-and-young-adults

Childhood brain tumors that form working electrical connections with healthy neurons grow more slowly in animals treated with an anti-seizure drug, Stanford Medicine research showed. Read more: https://med.stanford.edu/news/all-news/2026/09/seizure-drug-gliomas.html

As more children survive cancer, doctors are shifting the focus from simply defeating the disease to protecting growth, fertility, heart health, learning and emotional well-being for decades to come. Read more: https://www.firstpost.com/health/childhood-cancer-why-surviving-the-disease-is-only-the-beginning-14045619.html

A new report in the New England Journal of Medicine by researchers at Baylor College of Medicine, Texas Children’s Hospital and Seattle Children’s describes a complete regression of hepatoblastoma, the most common pediatric liver cancer, in a 3-year-old treated with a novel immunotherapy. Read more: https://www.bcm.edu/news/care-study-reports-complete-regression-of-liver-cancer-in-a-child-treated-with-novel-immunotherapy

Beginning early next year, children and families in Niagara will have access to pediatric oncology care closer to home through the new POGO Satellite Clinic at the Marotta Family Hospital. Read more: https://www.pogo.ca/pediatric-cancer-care-coming-closer-to-home-for-niagara-families

Scientists have found that certain chemotherapy drugs can age children’s healthy cells, causing the same amount of DNA damage in a short period that would normally accumulate over decades in middle-aged adults. Read more: https://www.insideprecisionmedicine.com/topics/oncology/childhood-chemotherapy-leaves-lasting-dna-damage-in-healthy-tissues/

Survival rates for childhood cancer now exceed 80%—but this also means more children are living with the long-term emotional and psychosocial impacts of cancer. Read more: https://medicalxpress.com/news/2026-09-children-cancer.html

But five-year survival answers only one question: whether a child lived through the immediate threat of cancer. It says much less about what happens at 25, 40, or 60—decades after the last dose of chemotherapy, a biologic, or the final radiation treatment. That question, largely invisible in headline survival statistics, is the subject of one of the longest-running and most influential research efforts in childhood cancer: the Childhood Cancer Survivor Study (CCSS). Read more

By reprogramming a patient’s own immune cells to recognize and destroy cancer, chimeric antigen receptor (CAR) T cells have significantly improved survival for children with refractory or relapsed B-cell acute lymphoblastic leukemia (B-ALL). However, decades of research and care have shown that treatment for pediatric cancers can affect survivors long into adulthood. So, learning from the past, a national group of physicians and scientists developing CAR T–cell therapies (the